A retrospective, cohort study directly comparing the safety and effectiveness among the four DOACs using the Japan Medical Data Center (JMDC) claims database
Latest Information Update: 02 Feb 2022
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary)
- Indications Embolism; Stroke
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 02 Feb 2022 New trial record